solution. In addition, FDA will make internal changes to intensify its ability to surface and address crucial issues and to support high-priority critical path research efforts.
Challenge and Opportunity on the Critical Path to New Medical Products (March 2004)
Full Report (PDF) Available: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
White Paper Executive Summary Available: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html#execsummary
Critical Path News Release Available: http://www.fda.gov/bbs/topics/news/2004/NEW01035.html
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Appendix C: The Critical Path to New Medical Products ."
The Threat of Pandemic Influenza: Are We Ready? Workshop Summary . Washington, DC: The National Academies Press,
Please select a format: